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The present paper aims to evaluate antihyperglycemic activity of methanol extract of Citrus limetta fruit peel (MECL) in
streptozotocin-induced (STZ; 65mg/kg b.w.) diabetic rats. Three days after STZ induction, diabetic rats received MECL orally
at 200 and 400mg kg−1 body weight daily for 15 days. Glibenclamide (0.5mg kg−1 p. o.) was used as reference drug. Blood glucose
levels were measured on 0th, 4th, 8th, and 15th days of study. Serum biochemical parameters namely, SGOT, SGPT and ALP
were estimated. The TBARS and GSH levels of pancreas, kidney, and liver were determined. MECL signiﬁcantly (P<0.001) and
dose dependently normalized blood glucose levels and serum biochemical parameters, decreased lipid peroxidation, and recovered
GSH as compared to those of STZ control. The present paper infers that in STZ-induced diabetic Wistar rats, C. limetta fruit peel
demonstrated a potential antihyperglycemic eﬀect which may be attributed to its antioxidant property.
1.Introduction
Diabetes mellitus (DM) is a chronic disease which is
caused either by inherited disability or acquired deﬁciency
in production of the hormone insulin and its subsequent
inability to regulate the blood glucose level and also where
there is suﬃcient production of insulin but the insulin
secreted is unable to regulate the blood glucose levels. The
outcome of the above two conditions is that there is an
increasedlevelofbloodglucosewhichinturndamagesmany
of the vital organs (kidney, eye, etc.) of the body [1]. There
is increasing demand by patients to use natural products
with antidiabetic activity due to side eﬀects associated with
the use of insulin and oral hypoglycemic agents [2–4].
Various traditional medicinal plants reported to have proven
hypoglycaemic properties such as Allium sativum (Garlic),
Azadirachta indica (Neem), Vinca rosea (Vinca), Trigonella
foenum-graceum (Fenugreek), Momordica charantia (Bitter
gourd),andOcimumscantum(Tulsi).Citrusfruitshavebeen
recommended in traditional herbal medicine as the source
of diabetic medication or remedy for diabetes [5]. Citrus
fruits are abundant in the Indian subcontinent. Lemon, lime,
pomelo, sweet lime, and orange, and so forth are cultivated
in abundance in diﬀerent regions of India. The citrus fruits
are well recognized for their various ethnomedicinal uses.
These properties are attributed to their ﬂavonoids and
limonoidswhichareproventopossesanti-inﬂammatoryand
antitumor eﬀects [6, 7]. The peels are rich in pectin which
is known to possess blood sugar lowering and cholesterol
lowering properties [8]. Other than these, carotenoids and
hydroxycinnamic acids are also abundant in citrus peels [9,
10].Hydroxycinnamicacidcompoundsinhibittheoxidation
of low-density lipoproteins [11] and have anticancer [12]
and antimicrobial activities [13]. A high carotenoid intake
alsodecreasestheriskofcancer,cataracts,andcardiovascular
diseases [14].
According to Andrade-Citto (1995), Citrus limetta Risso
(Rutaceae) is known to be an antihyperglycemic plant in
Mexican folklore [5], C. limetta fruits and leaves are used2 ISRN Endocrinology
f o rc o m m o nc o l d[ 15]; decreasing cholesterol level, fever
regulation, regulating inﬂammation, digestive disorders, and
sof o rthasw ellasb loodp r ess ur emod ulat o r[16]. Flavonoids
hespiridin and naringin are found to be present in the peel
andinnerpartofthefruitofCitruslimetta[17].Theessential
oils α-pinene, β-pinene, sabinene, β-myrcene, p-cymene,
limonene, γ-terpinene, neryl acetate, β-bisabolene, and α-
bergamotene were isolated from the zests of Citrus limetta
Risso [18]. Limonene, γ-terpinene was isolated from the
peel, and their minimum inhibitory concentration (MIC)
and maximal tolerated concentration (MTC) were estimated
against Pseudomonas putida [19].
The leaf extract of this plant was evaluated for its antag-
onistic activity on the hypertensive action of angiotensin II
[20]. The fruit has shown anti-inﬂammatory and antithrom-
botic actions [21, 22]. Present study aimed to explore the
antihyperglycemic potential of Citrus maxima leaf against
streptozotocin-induced diabetic rats.
2.MaterialsandMethods
2.1. Plant Material. C. limetta fruits were collected from
Nadia region of West Bengal, India in the months of March-
April, 2007. The plant material was authenticated by the
BotanicalSurveyofIndia,Shibpur,Howrah,andthevoucher
specimen (PMU-2/JU/2007). It is stored in our laboratory
for further references.
2.2. Extraction. Fresh fruit peels of C. limetta were taken
and grounded, and about 500g of the plant material was
consecutively macerated for seven days each in petroleum
ether, ethyl acetate, chloroform, and methanol, respectively.
On basis of the preliminary phytochemical tests conducted,
the methanol extract was found to be rich in terms of
chemical constituents and therefore was selected for the
hypoglycaemic activity. The methanol was removed under
reduced pressure to obtain a semisolid mass (MECL, yield
10.56%w/w). The MECL was then stored in vacuum
desiccator until used. The plant extract was subjected
to screening for various phytochemicals. The presence of
steroids, alkaloids, tannins, ﬂavonoids, glycosides, and so
forth was established in the MECL [23].
2.3. Chemicals. Glibenclamide tablet (DaonilTM, Hoechst,
India), streptozotocin (Himedia, Mumbai, India), 5,5-dithio
bis-2 nitro benzoic acid (DTNB), reduced glutathione (Sisco
Research Lab, Mumbai, India), thiobarbituric acid (TBA),
trichloroacetic acid (TCA), and nitroblue tetrazolium (NBT)
were used. All the other reagents used were of AR grade.
2.4. Animals. Six- to eight-week-old male Wistar albino rats
(180 ± 20g) were obtained from Ghosh and Co., Kolkata.
They were acclimatized to the laboratory conditions prior to
the study for seven days. The animals were kept at 25 ± 2◦C
and a relative humidity of 40–45% with alternative day and
night cycles of 12 hours each. The animals had free access to
pellet food (Hindustan Lever, Mumbai, India) and water ad
libitum.
Table 1: Eﬀect of MECL in glucose-loaded hyperglycemic rats.
Treatments Dose
Blood glucose concentration (mg/dL)
0h 1h 2h
Control — 82.3 ±1.4 183.7 ±7.4 134.7 ±10.7
MECL 200mg/kg
(p.o.) 77.3 ±5.2∗ 151.7 ±3.8∗ 93.3 ±2.8∗
MECL 400mg/kg
(p.o.) 83.4 ±2.4∗ 102.4 ±5.6∗ 84.7 ±2.7∗
Values are expressed as mean ± SEM (n = 6); ∗P<0.05 when compared
with control group.
Table 2: Hypoglycemic activity of diﬀerent doses of MECL in
normal rats.
Group Dose Blood glucose level mg/dL
0th hour 2 hour 30min
Saline control 5mL/kg (p.o.) 79.62 ±4.47 8 .66 ±1.4
MECL 200mg/kg (p.o.) 96.1 ±1.01∗ 87.7 ±2.2∗
MECL 400mg/kg (p.o.) 97.3 ±1.2∗ 65.7 ±4.2∗
Glibenclamide 0.5mg/kg (p.o.) 82.5 ±1.4∗ 77.83 ±2.5∗
Values are expressed as mean ± SEM (n = 6); ∗P<0.001 compared with
saline control group.
2.5. Acute Toxicity. The acute toxicity of the extract was
determined according to the OECD guideline no. 420 [24].
Male albino mice weighing 27–30g were used for this study.
MECL was given to four groups (n = 5) of animals at 5,
50, 300, and 2000mg/kg b.w. p. o. The treated animals were
u n d e ro b s e r v a t i o nf o r1 4d a y s ,f o rm o r t a l i t ya n dg e n e r a l
behaviour. No death was observed till the end of the study.
The test samples were found to be safe up to the dose of
2000mg/kg b.w.
2.6. Eﬀect on Glucose Tolerance in Rats. The animals were
divided into four groups. Group I served as negative control
group (0.9% NaCl, p. o). Group II and III were treated with
MECL at dose levels 200 and 400mgkg−1 b.w. p. o., respec-
tively. Group IV was treated with 0.5mgkg−1 glibenclamide
p. o. Zero hour-blood sugar levels were determined on 18-
hour fasted animals. After 30min of drug treatment the
a n i m a l sw e r ef e dw i t hg l u c o s e( 5g −1 kg) and blood glucose
was determined after 30 minutes, 1, 2, and 3h of the glucose
load [25]. The blood sugar level was measured using “Accu-
chek Active” Test strip in Accu-chek Active Test meter.
2.7. Oral Hypoglycaemic Activity in Normal Rats. Healthy
male Wistar albino rats weighing 180 ± 20g were selected
for the study. The animals used for the study were fasted for
twelve hours. The animals were classiﬁed into four groups
(n = 6 ) .G r o u pIs e r v e da ss a l i n ec o n t r o l( 5 m L k g −1 b.w.
0.9% NaCl p. o.); Groups II and III were treated with MECL
at dose levels 200 and 400mgkg−1 b . w .p .o .G r o u pI Vw a s
treatedwithglibenclamide(0.5mgkg−1 p.o.).Bloodsamples
were collected from the tail tip at 0 (before oral administra-
tion) and 2 hours 30 minutes after drug administration. The
blood sugar level was measured using “Accu-chek Active”
Test strip in Accu-chek Active Test meter.ISRN Endocrinology 3
Table 3: Eﬀect of diﬀerent doses of MECL on blood sugar level of normal and hyperglycaemic rats.
Group Dose
Blood glucose level mg/dL
0th day 4th day 8th day 15th day
Saline control 5mL/kg (p.o.) 79.62 ±4.47 8 .23 ±4.27 8 .16 ±2.47 8 .12 ±3.1
STZ control 65mg/kg (i.p.) 267.8 ±12.3∗ 288.7 ±15.6∗ 287.3 ±6.3∗ 294.8 ±2.8∗
STZ + MECL 200mg/kg (p.o.) 266.5 ±4.6∗∗ 100.6 ±4.4∗∗ 74.9 ±5.8∗∗ 74.2 ±2.7∗∗
STZ + MECL 400mg/kg (p.o.) 246.2 ±3.2∗∗ 93.8 ±2.9∗∗ 81.42 ±2.7∗∗ 79.3 ±3.02∗∗
STZ + Glibenclamide 0.5mg/kg (p.o.) 281.2 ±0.3∗∗ 96.3 ±4.6∗∗ 77.83 ±6.9∗∗ 74.7 ±1.7∗∗
Values are expressed as mean ± SEM (n = 6); ∗P<0.001 compared with saline control group and ∗∗P<0.001 compared with STZ-control group.
Table 4: Eﬀe c to nb o d yw e i g h to fd i ﬀerent doses of MECL in
normal and hyperglycaemic rats.
Group Dose
Body weight in grams
0th day 15 th Day
Saline control 5mL/kg (p.o.) 176.16 ±7.51 197 ±5.8
STZ control 65mg/kg (i.p.) 174.17 ±1.3∗ 116.25 ±1.9∗
STZ + MECL 200mg/kg (p.o.) 185.8 ±1.7∗∗ 142 ±1.4∗∗
STZ + MECL 400mg/kg (p.o.) 171.7 ±2.1∗∗ 140.8 ±1.1∗∗
STZ +
Glibenclamide 0.5mg/kg (p.o.) 182.32±6.4∗∗ 173.23±9.5∗∗
Values are expressed as mean ± SEM (n = 6); ∗P<0.001 compared with
saline control group and ∗∗P<0.001 compared with STZ-control group.
2.8. Induction of Experimental Diabetes. Streptozotocin was
administered to 18-hour fasted rats and observed for 5 days.
STZ was freshly dissolved in citrate buﬀer (0.01M, pH 4.5).
The injection volume was prepared to contain 65mgmL−1
and injected as 0.1mL 100g−1 of body weight [26]. After
5 days the fasting blood glucose level was measured on
overnight fasted rats by using “Accu-chek Active” Test strip
in Accu-chek Active Test meter. The animals that developed
blood glucose level of more than 250mgdL−1 were selected
for the study.
2.9. Treatment of Diabetic Animals. Thirty male Wistar
albino rats (160–200g) were divided into ﬁve groups (n = 6)
out of which six normal animals were kept as nondiabetic
saline control. Group II served as diabetic control. Group
III and IV received MECL (200 and 400mgkg−1 b.w. p.
o.) and Group V received reference drug glibenclamide
(0.5mgkg−1 b.w. p. o.) daily for 15 days, respectively [27].
2.10. Sample Collection and Biochemical Studies. Fasting
blood sugar of the animals was determined on 0th, 5th,
8th, and 15th day collected from the tail vein. On 15th day
blood was collected from the retro orbital plexus of the eye
for the determination of SGPT, SGOT, and ALP. All the
animals from diﬀerent groups were sacriﬁced on the 15th
day and their liver, kidney, and pancreas were isolated for the
estimation of TBARS and GSH. Thiobarbituric acid reactive
substances (TBARS) were estimated in the liver and kidney
by the method of Fraga et al. (1981) and are expressed as
mmol100g−1 oftissue[28].Reducedglutathione(GSH)was
determined by the method of Ellman [29], and the GSH
activity is expressed as mg 100g−1 of tissue [29].
2.11. Statistical Analysis. All the values of body weight, fast-
ing blood sugar, and biochemical parameters were expressed
as mean ± standard error of mean (SEM) and were analysed
for ANOVA and Dunnett’s “t” test. The values of P<0.001
were considered statistically very signiﬁcant and P<0.05
were considered as signiﬁcant.
3. Results
Acute toxicity study was carried out on Swiss albino mice
whichshowedthatMECLwassafeupto2000mgkg−1 b.w.p.
o.Preliminaryphytochemicalstudyindicatedthepresenceof
ﬂavonoids, alkaloids, tannins, and saponin in MECL.
The eﬀect of MECL in lowering the blood sugar level in
glucose-overloaded rats is summarized in Table 1.M E C L -
treated groups have shown signiﬁcant (P<0.05) decrease
in the blood sugar level of the glucose overloaded rats.
The eﬀect of MECL in lowering of blood sugar levels of
normal rats are summarized in Table 2. The MECL-treated
groupsshowsigniﬁcantreductioninthebloodsugarlevelsas
comparedtothereferencedruginadose-dependantmanner.
The measured blood glucose levels of nondiabetic and
STZ-induced diabetic rats are shown in Table 3. Administra-
tion of MECL in STZ-induced diabetic rats, at the doses of
200 and 400mgkg−1 b.w., produced a signiﬁcant reduction
in blood glucose levels when compared with the STZ-control
group.
The body weights of normal and diabetic rats are sum-
m a r i z e di nT a b l e4. The ﬁnal body weights were signiﬁcantly
decreased in the STZ control group when compared with the
saline control group. The table exhibited an improvement of
body weight after treatment with the extract when compared
to that of the STZ control group.
In case of biochemical estimation, improvement of
serum enzyme levels were observed in the treated groups
with respect to the diabetic control group as shown in
Table 5. The level of TBARS and GSH activities in pancreatic,
kidney, and liver tissues of experimental diabetic rats are
shown in Table 6. There was a signiﬁcant elevation of lipid
peroxide in the pancreas, liver, and kidney with diabetes
when compared to the saline control group. It was seen that
the administration of MECL helped to decrease pancreatic,4 ISRN Endocrinology
Table 5: Eﬀect on diﬀerent serum enzyme levels of diﬀerent doses of MECL in normal and hyperglycaemic rats.
Group Dose SGOT (IU/L) SGPT (IU/L) ALP (KA units)
Saline control 5mL/kg (p.o.) 130.5 ±1.39 7 .96 ±0.15 28.33 ±1.76
STZ control 65mg/kg (i.p.) 242.6 ±1.21∗ 206.7 ±0.14∗ 73.01 ±1.81∗
STZ + MECL 200mg/kg (p.o.) 177.04 ±0.8∗∗ 131.3 ±0.14∗∗ 47.3 ±1.2∗∗
STZ + MECL 400mg/kg (p.o.) 158.79 ±0.84∗∗ 125.74 ±0.73∗∗ 43.2 ±2.4∗∗
STZ + Glibenclamide 0.5mg/kg (p.o.) 143.38 ±2.26∗∗ 119.5 ±1.22∗∗ 37.21 ±1.65∗∗
Values are expressed as mean ± SEM (n = 6); ∗P<0.001 compared with saline control group and ∗∗P<0.001 compared with STZ-control group.
Table 6: Eﬀect of MECL on diﬀerent tissue enzymes of normal and hyperglycaemic rats.
Group Dose
Lipid peroxidation (mM 100g−1 of tissue ) Glutathione (mg 100g−1 of tissue)
Pancreas Liver Kidney Pancreas Liver Kidney
Saline control 5mL/kg (p.o.) 1.14 ±0.08 1.02 ±0.05 1.49 ±0.13 4 .56 ±3.24 9 .3 ±2.12 3 .6 ±1.3
STZ control 65mg/kg (i.p.) 1.8 ±0.09∗ 1.85 ±0.09∗ 2.34 ± 0.6∗ 13.7 ±1.4∗ 25.9 ±1.5∗ 6.4 ±2.4∗
STZ + MECL 200mg/kg (p.o.) 1.4 ±0.02∗∗ 1.4 ±0.08∗∗ 1.7 ±0.08∗∗ 41.09±0.024∗∗ 27.4 ±0.62∗∗ 18.86±0.16∗∗
STZ + MECL 400mg/kg (p.o.) 1.31 ± 0.09∗∗ 1.12 ±0.07∗∗ 1.62 ±0.02∗∗ 36.08 ±0.05∗∗ 31.75±0.031∗∗ 17.14±0.29∗∗
STZ +
Glibenclamide 0.5mg/kg (p.o.) 1.23 ± 0.07∗∗ 1.07 ±0.02∗∗ 1.51 ±0.06∗∗ 41.31 ±2.3∗∗ 41.78 ±2.1∗∗ 19.61 ±1.5∗∗
Values are expressed as mean ± SEM (n = 6); ∗P<0.001 compared with saline control group and ∗∗P<0.001 compared with STZ-control group.
hepatic, and renal TBARS levels, which is an indication of
the inhibition of oxidative damage of the said tissues. There
was also a signiﬁcant decrease in the level of GSH in the
STZ control group when compared with the saline control
group. Administration of MECL at the doses of 200 and
400mgkg−1 b.w. increased the GSH level in the liver and
kidney of STZ-induced rats.
4. Discussion
Streptozotocin (STZ) is widely used for the induction of
diabetes mellitus in experimental animals. It is postulated to
induce diabetes by the degeneration and necrosis of β cells of
islet of langerhans of pancreas, which leads to the reduction
in insulin release [30]. The ability of STZ to selectively enter
the β cells via the low-aﬃnity glucose transporter GLUT2
in the plasma membrane can be attributed to the presence
of glucose moiety in it. After STZ enters the cells it gets
converted to reactive methylcarbonium ions that alkylate
DNA and induce free radical generation which target the
DNA sugar moiety and result in DNA strand breakage [31].
In the present investigation it was observed that oral
administration of the MECL at the doses of 200 and
400mgkg−1 b.w. produced eﬀective hypoglycemic and anti-
hyperglycemic activity in normoglycemic, glucose over-
loaded, as well as STZ-induced diabetic rats. MECL also
possessed a signiﬁcant controlling eﬀect in the loss of body
weight that occurred in diabetic rats. The food intake of the
STZcontroldecreasedsigniﬁcantly.Forallothergroupsfood
intake was comparable to that of saline control.
Preliminary phytochemical analysis of MECL indicated
the presence of ﬂavonoids. Flavonoids are polyphenolic
compounds that are well-known antioxidants because of
their electron-donating properties, either scavenging the
principal propagating radicals or halting the radical chain. In
vitrofree radical scavenging activity of MECL was performed
by the authors, and the extract was found to have signiﬁcant
free radical scavenging activity when tested against diﬀerent
free radicals [32].
Elevated levels of the serum enzymes (SGPT, SGOT, and
ALP) in the diabetic control group reﬂect the signiﬁcant
alteration of liver function by STZ induction [33]. Treatment
with MECL restored the elevated enzyme levels to normal
level in a dose-dependent manner (P<0.001).
Under normal physiological conditions, the human body
can compensate for a mild degree of oxidative stress,
and remove oxidatively damaged molecules by activating
antioxidant enzymes. These antioxidants are able to resist
oxidative stress by scavenging free radicals, inhibiting lipid
peroxidation, and increasing glutathione [33].
Lipid peroxidation is a natural phenomenon involved in
peroxidative loss at unsaturated lipids, thus bringing about
lipid degradation and membrane disorganization. Peroxi-
dized lipid has been considered to play a signiﬁcant role
in the pathogenesis of several diseases, and may be taken
as a molecular mechanism of cell injury under pathological
conditions. Lipid peroxidation is usually measured through
its catabolite malondialdehyde (MDA) in terms of TBARS
(thiobarbituric acid reactive substances) as a marker of
oxidative stress [33]. In the current study it was observed
that there was a signiﬁcant decrease in the TBARS levels of
the MECL-treated rats in comparison to that of the diabetic
control group.
Glutathione (GSH) is one of the abundant tripeptide
nonenzymatic biological antioxidants present in the liver
and kidney. GSH plays multifunctional role in antioxidant
defence. It is a direct scavenger of free radicals as well as
a cosubstrate for peroxide detoxiﬁcation by glutathioneISRN Endocrinology 5
peroxidases [34]. It is postulated that a decrease in tissue
GSH is due to either decreased synthesis or increased
degra-dation of GSH by oxidative stress [35]. In the current
study it is observed that MECL was able to decrease elevated
levels of GSH in comparison to the diabetic control rats.
The present study shows that the methanol extract of the
fruit peels of C. limetta has potent antihyperglycemic activity
againstSTZ-induceddiabetesaswellashavinghypoglycemic
activity in normoglycemic rats and in glucose overloaded
rats. The Citrus plants are rich in ﬂavonoids which are
polyphenolic compounds having potent antioxidant prop-
erty.
As discussed earlier in the introduction section, the fruit
peel of Citrus limetta contains the ﬂavonoids hesperidin and
naringin. Hesperidin and naringin both are proven to be
potenthypoglycaemicagents,andtheirhypoglycaemicactiv-
ity is postulated to be partly mediated by hepatic glucose-
regulating enzymes in C57BL/KsJ-db/db mice [36]. Dietary
hesperidin also exerts hypoglycemic and hypolipidemic
eﬀects in streptozotocin-induced diabetic rats [37]. Naringin
provided a signiﬁcant amelioration of hypoglycaemic and
antioxidant activity in STZ-induced diabetic rats [38].
Therefore,itcanbepostulatedthatthepresenceofﬂavonoids
in the extract might be the reason of the antihyperglycemic
action shown by MECL. Further investigation in this line can
pinpoint the exact mechanism of action of Citrus limetta.
In the future identifying the active biological principle of C.
limetta may provide novel, safe antidiabetic compound.
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